General information about company		
Scrip code	530125	
NSE Symbol		
MSEI Symbol		
ISIN*	INE103E01016	
Name of company	Samrat Pharmachem Limited	
Type of company		
Class of security	Equity	
Date of start of financial year	01-04-2022	
Date of end of financial year	31-03-2023	
Date of board meeting when results were approved	14-11-2022	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-09-2022	
Description of presentation currency	INR	
Level of rounding used in financial results	Lakhs	
Reporting Quarter	Half yearly	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited	Unaudited	
Segment Reporting	Single segment	
Description of single segment	Pharmaceutical Chemicals	
Start date and time of board meeting	14-11-2022 14:00	
End date and time of board meeting	14-11-2022 15:30	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	

	Financial Results – Ind-AS					
	Particulars  3 months/ 6 months ended (dd-mm-yyyy)  4 date figures for current period ended (dd-mm-yyyy)					
A	Date of start of reporting period	01-07-2022	01-04-2022			
В	Date of end of reporting period	30-09-2022	30-09-2022			
С	Whether results are audited or unaudited	Unaudited	Unaudited			
D	Nature of report standalone or consolidated	Standalone	Standalone			
Part I	Blue color marked fields are non-mandatory. For Conmonths ended, in such case zero shall be inserted in th		any has no figures for 3 months / 6			
1	Income					
	Revenue from operations	7111.75	15762.42			
	Other income	15.93	18.46			
	Total income	7127.68	15780.88			
2	Expenses					
(a)	Cost of materials consumed	6874.54	14441.56			
(b)	Purchases of stock-in-trade	0	0			
(c)	Changes in inventories of finished goods, work-in- progress and stock-in-trade	-821.34	-1234.91			
(d)	Employee benefit expense	43.17	84.32			
(e)	Finance costs	23.6	46.21			
(f)	Depreciation, depletion and amortisation expense	15.99	31.76			
(f)	Other Expenses					
1	Manufacturing Expenses	88.75	184.75			
2	Administration Expenses	29.36	61.38			
3	Selling & Distribution Expenses	71.57	111.1			
10						
	Total other expenses	189.68	357.23			
	Total expenses	6325.64	13726.17			

	Financial Results – Ind-AS				
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)		
Α	Date of start of reporting period	01-07-2022	01-04-2022		
В	Date of end of reporting period	30-09-2022	30-09-2022		
С	Whether results are audited or unaudited	Unaudited	Unaudited		
D	Nature of report standalone or consolidated	Standalone	Standalone		
Part I	Blue color marked fields are non-mandatory. For Consolidated Remonths ended, in such case zero shall be inserted in the said column	sults, if the company has n.	no figures for 3 months / 6		
3	Total profit before exceptional items and tax	802.04	2054.71		
4	Exceptional items	0	0		
5	Total profit before tax	802.04	2054.71		
7	Tax expense				
8	Current tax	221.65	534.6		
9	Deferred tax	-10.89	-7.81		
10	Total tax expenses	210.76	526.79		
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0		
14	Net Profit Loss for the period from continuing operations	591.28	1527.92		
15	Profit (loss) from discontinued operations before tax	0	0		
16	Tax expense of discontinued operations	0	0		
17	Net profit (loss) from discontinued operation after tax	0	0		
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0		
	Total profit (loss) for period	591.28	1527.92		

	Financial Results – Ind-AS					
	Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)			
A	Date of start of reporting period	01-07-2022	01-04-2022			
В	Date of end of reporting period	30-09-2022	30-09-2022			
С	Whether results are audited or unaudited	Unaudited	Unaudited			
D	Nature of report standalone or consolidated	Standalone	Standalone			
	Other comprehensive income [Abstract]					
1	Amount of items that will not be reclassified to profit and loss					
	Total Amount of items that will not be reclassified to profit and loss	0	0			
2	Income tax relating to items that will not be reclassified to profit or loss	0	0			
3	Amount of items that will be reclassified to profit and	loss				
	Total Amount of items that will be reclassified to profit and loss					
4	Income tax relating to items that will be reclassified to profit or loss	0	0			
5	Total Other comprehensive income	0	0			

	Financial Resu	lts – Ind-AS	
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-07-2022	01-04-2022
В	Date of end of reporting period	30-09-2022	30-09-2022
С	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidate months ended, in such case zero shall be inserted in the said c		has no figures for 3 months / 6
23	Total Comprehensive Income for the period	591.28	1527.92
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to	L	
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	308.97	308.97
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	19.14	49.45
	Diluted earnings (loss) per share from continuing operations	19.14	49.45
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	19.14	49.45
	Diluted earnings (loss) per share from continuing and discontinued operations	19.14	49.45
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block	
extual Information(1)	1. The above results were reviewed by the Audit Committee of the Board of Directors.  2. The Statutory Auditors have carried out a limited review of the results for the quarted ended 30th September, 2022  3. The above unaudited results have been taken on record by the Board of Directors at it Meeting held on Monday, 14 November, 2022 at the Corporate Office of the Company.  4. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with efffect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 30 September 2022 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.  5. The Company manufactures phamaceutical chemicals, which is a single business segment.  6. Figures for the previous period have been regrouped / reclassfied, wherever necessary.

	Statement of Asset and Liabilitie	es
	Particulars	Half year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2022
	Date of end of reporting period	30-09-2022
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
A	ssets	
1 N	on-current assets	
Pı	roperty, plant and equipment	982.82
C	apital work-in-progress	
In	envestment property	
G	oodwill	0
О	ther intangible assets	0.8
In	ntangible assets under development	
В	iological assets other than bearer plants	
In	evestments accounted for using equity method	
N	on-current financial assets	
N	on-current investments	0
Tı	rade receivables, non-current	
L	oans, non-current	23.4
О	ther non-current financial assets	
	Total non-current financial assets	23.4
D	referred tax assets (net)	
О	ther non-current assets	181.13
	Total non-current assets	1188.15
2 C	urrent assets	
In	ventories	3381.87
C	urrent financial asset	
C	urrent investments	189.16
Tı	rade receivables, current	5370.02
C	ash and cash equivalents	898.1
В	ank balance other than cash and cash equivalents	0
L	oans, current	0
О	ther current financial assets	
	Total current financial assets	6457.28
C	urrent tax assets (net)	
О	ther current assets	72.54
	Total current assets	9911.69

Statement of Asset and Liabilities	
Particulars	Half year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2022
Date of end of reporting period	30-09-2022
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
3 Non-current assets classified as held for sale	
4 Regulatory deferral account debit balances and related deferred tax Assets	
Total assets	11099.84
Equity and liabilities	
Equity	
Equity attributable to owners of parent	
Equity share capital	308.97
Other equity	5901.13
Total equity attributable to owners of parent	6210.1
Non controlling interest	
Total equity	6210.1
Liabilities	
Non-current liabilities	
Non-current financial liabilities	
Borrowings, non-current	683.58
Trade payables, non-current	
Other non-current financial liabilities	
Total non-current financial liabilities	683.58
Provisions, non-current	0
Deferred tax liabilities (net)	38.28
Deferred government grants, Non-current	
Other non-current liabilities	
Total non-current liabilities	721.86
Current liabilities	
Current financial liabilities	
Borrowings, current	2179.53
Trade payables, current	1445.78
Other current financial liabilities	
Total current financial liabilities	3625.31
Other current liabilities	7.66
Provisions, current	534.91
Current tax liabilities (Net)	
Deferred government grants, Current	
Total current liabilities	4167.88
3 Liabilities directly associated with assets in disposal group classified as held for sale	
4 Regulatory deferral account credit balances and related deferred tax liability	
Total liabilities	4889.74

]	Format for Reporting Segmenet wise Reven	ue, Results and Capital Em	ployed along with the company results		
	Particulars	3 months/ 6 month ended (dd- mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)		
	Date of start of reporting period	01-07-2022	01-04-2022		
	Date of end of reporting period	30-09-2022	30-09-2022		
	Whether accounts are audited or unaudited	Unaudited	Unaudited		
	Nature of report standalone or consolidated	Standalone	Standalone		
1	Segment Revenue (Income)				
	(net sale/income from each segment should be discle	osed)			
	Total Segment Revenue				
	Less: Inter segment revenue				
	Revenue from operations				
2	Segment Result				
	Profit (+) / Loss (-) before tax and interest from each segment				
	Total Profit before tax				
	i. Finance cost				
	ii. Other Unallocable Expenditure net off Unallocable income				
	Profit before tax				
3	(Segment Asset - Segment Liabilities)				
	Segment Asset				
	Total Segment Asset				
	Un-allocable Assets				
	Net Segment Asset				
4	Segment Liabilities				
	Segment Liabilities				
	Total Segment Liabilities				
	Un-allocable Liabilities				
	Net Segment Liabilities				
	Disclosure of notes on segments				

	Particulars	6 months ended (dd-mm- yyyy)
A	Date of start of reporting period	01-04-2022
В	Date of end of reporting period	30-09-2022
C	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
art I	Blue color marked fields are non-mandatory.	
	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	2054.71
	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	46.21
	Adjustments for decrease (increase) in inventories	-2140.28
	Adjustments for decrease (increase) in trade receivables, current	-1012.56
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-21.62
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-894.64
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-80.05
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	31.76
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	9.86
	Adjustments for interest income	4.45
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	-8.94
	Adjustments for undistributed profits of associates	0.54
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability	0
	partnerships	0
	Total adjustments for reconcile profit (loss)	-4094.43
	Net cash flows from (used in) operations	-2039.72
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	672.14
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	-2711.86

Cash flows from losing control of subsidiaries or other businesses	
Cash flows used in obtaining control of subsidiaries or other businesses	
Other cash receipts from sales of equity or debt instruments of other entities	
Other cash payments to acquire equity or debt instruments of other entities	
Other cash receipts from sales of interests in joint ventures	
Other cash payments to acquire interests in joint ventures	
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	
Proceeds from sales of property, plant and equipment	
Purchase of property, plant and equipment	16.8
Proceeds from sales of investment property	
Purchase of investment property	179.2
Proceeds from sales of intangible assets	
Purchase of intangible assets	
Proceeds from sales of intangible assets under development	
Purchase of intangible assets under development	
Proceeds from sales of goodwill	
Purchase of goodwill	
Proceeds from biological assets other than bearer plants	
Purchase of biological assets other than bearer plants	
Proceeds from government grants	
Proceeds from sales of other long-term assets	
Purchase of other long-term assets	
Cash advances and loans made to other parties	
Cash receipts from repayment of advances and loans made to other parties	
Cash payments for future contracts, forward contracts, option contracts and swap contracts	
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	
Dividends received	9.8
Interest received	4.4
Income taxes paid (refund)	
Other inflows (outflows) of cash	-22
Net cash flows from (used in) investing activities	-406.7
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries	
Payments from changes in ownership interests in subsidiaries	
Proceeds from issuing shares	
Proceeds from issuing other equity instruments	
Payments to acquire or redeem entity's shares	
Payments of other equity instruments	
Proceeds from exercise of stock options	
Proceeds from issuing debentures notes bonds etc	
Proceeds from borrowings	2111.1
Repayments of borrowings	
Payments of finance lease liabilities	
Payments of lease liabilities	
Dividends paid	
Interest paid	46.2
Income taxes paid (refund)	
Other inflows (outflows) of cash	
Net cash flows from (used in) financing activities	2064.9

Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	-1053.65
Cash and cash equivalents cash flow statement at beginning of period	1470.35
Cash and cash equivalents cash flow statement at end of period	416.7